Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib

Christopher L. Heidler(Heidelberg University), Andreas E. Kulozik(Heidelberg University)

International Journal of Cancer

November 29, 2019

10.1002/ijc.32814

Cited by 26

Related Papers

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia

|Blood|2006|293

Plasticity of nuclear and cytoplasmic stress responses of RNA-binding proteins

|Nucleic Acids Research|2020|66

A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition

|Aging|2015|17

Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma

|Nature Communications|2024|10